MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells

Gene

Volumn 531, Issue 1, 2013, Pages 8-14

  Zhong, Shanliang ^a   Li, Wenjing ^b   Chen, Zhiyuan ^c   Xu, Jinjin ^a   Zhao, Jianhua ^a  

^a JIANGSU CANCER HOSPITAL   (China)

^b SUZHOU MUNICIPAL HOSPITAL   (China)

^c XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; MiR 222; MiR 29a; MiRNAs; PTEN; Resistance

Indexed keywords

DOCETAXEL; DOXORUBICIN; MICRORNA 100; MICRORNA 222; MICRORNA 29A; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5-DIPHENYLTETRAZOLIUM BROMIDE; ADR; ADRIAMYCIN; BREAST CANCER; DIMETHYL SULFOXIDE; DMEM; DMSO; DNA METHYLTRANSFERASE; DNMT; DOC; DOCETAXEL; DULBECCO'S MODIFIED EAGLE'S MEDIUM; IC50; INHIBITORY CONCENTRATION TO PRODUCE 50% CELL DEATH; MAPK; MESSENGER RNA; MICRORNA; MIR; MIR-222; MIR-29A; MIRNA; MIRNAS; MITOGEN-ACTIVATED PROTEIN KINASE; MRNA; MTT; PHOSPHATASE AND TENSIN HOMOLOG; PTEN; REAL-TIME QUANTITATIVE PCR; RESISTANCE; RT-QPCR;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICRORNAS; PTEN PHOSPHOHYDROLASE; RNA INTERFERENCE; TAXOIDS;

EID: 84884820584     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.08.062     Document Type: Article

References (26)

1. Ali A.Y., et al. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann. N. Y. Acad. Sci. 2012, 1271:58-67.
2. Anglicheau D., Muthukumar T., Suthanthiran M. MicroRNAs: small RNAs with big effects. Transplantation 2010, 90:105-112.
3. Chedotal A., Kerjan G., Moreau-Fauvarque C. The brain within the tumor: new roles for axon guidance molecules in cancers. Cell Death Differ. 2005, 12:1044-1056.
4. Chen G.Q., Zhao Z.W., Zhou H.Y., Liu Y.J., Yang H.J. Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med. Oncol. 2010, 27:406-415.
5. Chun-Zhi Z., et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer 2010, 10:367.
6. Fabbri M., et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15805-15810.
7. Garofalo M., et al. MiR-221 & 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009, 16:498-509.
8. Griffiths-Jones S., Grocock R.J., van Dongen S., Bateman A., Enright A.J. MiRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006, 34:D140-D144.
9. Griffiths-Jones S., Saini H.K., van Dongen S., Enright A.J. MiRBase: tools for microRNA genomics. Nucleic Acids Res. 2008, 36:D154-D158.
10. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5:522-531.
11. Ji N., Yuan J., Liu J., Tian S. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase. Acta Biochim. Biophys. Sin. (Shanghai) 2010, 42:854-862.
12. Krek A., et al. Combinatorial microRNA target predictions. Nat. Genet. 2005, 37:495-500.
13. Kutanzi K.R., Yurchenko O.V., Beland F.A., Checkhun V.F., Pogribny I.P. MicroRNA-mediated drug resistance in breast cancer. Clin. Epigenetics 2011, 2:171-185.
14. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
15. Meunier L., et al. Perinatal programming of adult rat germ cell death after exposure to xenoestrogens: role of microRNA miR-29 family in the down-regulation of DNA methyltransferases and Mcl-1. Endocrinology 2012, 153:1936-1947.
16. Miller T.E., et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem. 2008, 283:29897-29903.
17. Normanno N., et al. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. Breast Cancer Res. Treat. 2008, 112:25-33.
18. O'Driscoll L., Clynes M. Biomarkers and multiple drug resistance in breast cancer. Curr. Cancer Drug Targets 2006, 6:365-384.
19. Rao X., et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011, 30:1082-1097.
20. Rivera E., Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res. 2010, 12(Suppl. 2):S2.
21. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
22. Wang S., et al. Molecular imaging of p53 signal pathway in lung cancer cell cycle arrest induced by cisplatin. Mol. Carcinog. 2012, (http://dx.doi.org/10.1002/mc.21930).
23. Wind N.S., Holen I. Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int. J. Breast Cancer 2011, 2011:967419.
24. Yamada K.M., Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J. Cell Sci. 2001, 114:2375-2382.
25. Zhang S., Yu D. PI(3)king apart PTEN's role in cancer. Clin. Cancer Res. 2010, 16:4325-4330.
26. Zhao J.J., et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem. 2008, 283:31079-31086.